Skip to main content

Advertisement

Log in

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

An Erratum to this article was published on 14 October 2017

This article has been updated

Abstract

Purpose

To determine the efficacy and safety of sitagliptin when used with some therapeutic drugs to treat elderly patients.

Methods

Sitagliptin (50 mg/day) was added to the pre-existing therapy for type 2 diabetes. Changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was performed. These analyses were conducted as subanalyses of the JAMP study, which was an open-label observational study.

Results

For patients who were ≥65 years of age, the change in HbA1c level from baseline ranged from −0.50 to −0.87% at 3 months after starting treatment. There was no significant difference in the change in HbA1c level between the patients treated with different concomitant drugs. No significant difference in HbA1c variations at 3 and 12 months from baseline was noted among the three age groups (≥75, 65–74, and <65 years). Multiple regression analysis was performed, and it revealed that patients with higher HbA1c levels at baseline were likely to show decreased HbA1c levels, while those with higher triglyceride (TG) levels were unlikely to show decreased HbA1c levels.

Conclusion

Sitagliptin has the potential to both improve glycemic control and prevent hypoglycemia, and can be considered a potent alternative drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Change history

  • 14 October 2017

    Erratum to: Diabetol Int DOI 10.1007/s13340-017-0330-2.

References

  1. Ministry of Health, Labour and Welfare. Summary of “Patient Survey”. Tokyo: Ministry of Health, Labour and Welfare; 2015. http://www.mhlw.go.jp/english/database/db-hss/sps_2014.html. Accessed 26 Jul 2017

  2. Ministry of Health, Labour and Welfare. Results of “National Health and Nutrition Survey”. Tokyo: Ministry of Health, Labour and Welfare; 2015. http://www.mhlw.go.jp/stf/houdou/0000106405.html. Accessed 26 Jul 2017

  3. Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18(1):163–83.

    CAS  PubMed  Google Scholar 

  4. Araki A. Low well-being, cognitive impairment and visual impairment associated with functional disabilities in elderly Japanese patients with diabetes mellitus. Geriatr Gerontol Int. 2004;4(1):15–24.

    Article  Google Scholar 

  5. Ma F. Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up. J Alzheimers Dis. 2015;43(4):1441–9.

    CAS  PubMed  Google Scholar 

  6. Solini A. Renal insufficiency and cardiovascular events study group: age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(8):1253–61.

    Article  PubMed  Google Scholar 

  7. Huang ES. Rates of complications and mortality in older diabetes patients: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lind M. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55(11):2946–53.

    Article  CAS  PubMed  Google Scholar 

  9. Bremer JP. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32(8):1513–7.

  10. Aschner P. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–7.

    Article  CAS  PubMed  Google Scholar 

  11. Charbonnel B. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–43.

    Article  CAS  PubMed  Google Scholar 

  12. Rosenstock J. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–68.

    Article  CAS  PubMed  Google Scholar 

  13. Shankar R. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. Int J Clin Pract. 2015;69(6):626–31.

    Article  CAS  PubMed  Google Scholar 

  14. Hartley P. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, non-inferiority trial. Drugs Aging. 2015;32(6):469–76.

  15. Umezawa S. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15(34):1–8.

    CAS  Google Scholar 

  16. Hermansen K. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.

    Article  CAS  PubMed  Google Scholar 

  17. Sakura H. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016;16(1):70.

  18. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus (revision for international harmonization of HbA1c in Japan). J Jpn Diabetes Soc. 2012;55(7):485–504.

  19. Barzilia N. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–58.

    Article  Google Scholar 

  20. Round E. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–14.

    Article  CAS  PubMed  Google Scholar 

  21. Nelson EA. Aged heterogeneity: fact or fiction? The fate of diversity in gerontological research. Gerontologist. 1992;32(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  22. Goto A. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.

    Article  PubMed  Google Scholar 

  23. The Japan Diabetes Society. Diabetes in the elderly (including dementia). In: Guideline for the treatment for diabetes in Japan 2016. Tokyo: Nankodo; 2016. p. 411–48.

  24. Scott R. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–80.

    Article  CAS  PubMed  Google Scholar 

  25. Nonaka K. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–8.

    Article  CAS  PubMed  Google Scholar 

  26. Tada Y. Long-term efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Intern Med. 2016;55(10):1275–8.

    Article  CAS  PubMed  Google Scholar 

  27. Ching-Jung H. The durability of sitagliptin in elderly patients with type 2 diabetes. Clin Interv Aging. 2014;7(9):1905–11.

    Google Scholar 

  28. Harris MI. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Examination Survey. Diabetes Care. 1998;21(4):518–24.

    Article  CAS  PubMed  Google Scholar 

  29. Suh DC. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56(3):484–92.

    Article  PubMed  Google Scholar 

  30. Bosu R. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes. 2003;52(7):1738–48.

    Article  Google Scholar 

  31. Sakurai T. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus. Gerontology. 2010;56:141–9.

    Article  CAS  PubMed  Google Scholar 

  32. Zhuravlyova LV. The factors of the progression of metabolic disorders in the pancreas in patients with associated clinical variants of the chronic pancreatitis and type 2 diabetes mellitus. Lik Sprava. 2015;2015(5–6):46–51.

    Google Scholar 

  33. Iwamoto Y. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to express our sincere gratitude to Mr. Shogo Shishikura (MSD K.K.) (Teikyo University Graduate School of Public Health, MPH) for scientific advice, including references, when revising the manuscript. We would also like to thank Nouvelle Place Inc. for conducting the data analyses.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Noriko Ujihara.

Ethics declarations

Funding

This study was funded by the Japan Diabetes Foundation.

Conflict of interest

Hiroshi Sakura received honoraria from Mitsubishi Tanabe Pharma Corporation and a research grant from Ono Pharmaceutical Co., Ltd. The other authors declare that they have no conflict of interest.

JAMP Study Investigators

Akiko Sato (Maruyama Internal Medicine Clinic); Akira Miyashita (Miyashita Surgery Clinic); Asako Kokubo (Kokubo Clinic); Atsuro Tsuchiya (Tsuchiya Clinic); Dai Hirohara (Hanazono Clinic); Daiji Kogure (Kogure Clinic); Daijo Kasahara (Kasahara Clinic); Hideki Tanaka (Internal Medicine, Seiwa Clinic); Hideki Tanaka (Internal Medicine, Nishiarai Hospital); Hideo Tezuka (Tezuka Clinic); Hiroyuki Kuroki (Internal Medicine, Johsai Hospital); Jun Ogino (Department of Diabetes, Endocrine and Metabolic Diseases, Tokyo Women’s Medical University Yachiyo Medical Center); Kanu Kin (Internal Medicine, Nishiarai Lifestyle-Related Diseases Clinic); Kanu Kin (Internal Medicine, Nishiarai Hospital); Kazuko Muto (Tokyo Women’s Medical University); Kazuo Suzuki (Kenkokan Suzuki Clinic of Internal Medicine); Keiko Iseki (Iseki Clinic); Keita Watanabe (Watanabe Clinic); Kenshi Higami (Higami Hospital); Kenzo Matsumura (Matsumura Gastroenterological Clinic); Kiyotaka Nakajima (Ebisu Clinic); Koki Shin (Shin Clinic); Kuniya Koizumi (Kuniya Clinic); Maki Saneshige (Mugishima Medical Clinic); Makio Sekine (Sekine Clinic); Makoto Yaida (Urban Heights Clinic); Mari Kiuchi (physician, Kanauchi Medical Clinic); Mari Mugishima (Mugishima Medical Clinic); Mari Osawa (Department of Diabetes Mellitus, Institute of Geriatrics, Tokyo Women’s Medical University); Masae Banno (Banno Medical Clinic); Masahiro Yamamoto (Internal Medicine 1, Shimane University Faculty of Medicine); Masatake Hiratsuka (Higashishinagawa Clinic); Masumi Hosoya (Yasui Clinic); Michika Atsuta (Internal Medicine, Nishiarai Lifestyle-Related Diseases Clinic); Mitsutoshi Kato (Kato Clinic of Internal Medicine); Miwa Morita (Internal Medicine 1, Shimane University Faculty of Medicine); Munehiro Miyamae (Johsai Hospital); Mutsumi Iijima (Abe Hospital); Naomi Okuyama (Shinjuku Mitsui Building Clinic); Nobuo Hisano (Mejiro Medical Clinic); Norihiro Tsuchiya (Omotesando Naika Ganka); Rie Wada (Kanauchi Medical Clinic); Rie Wada (Nerimasakuradai Clinic); Ryuji Momose (Momo Medical Clinic); Sachiko Otake (Tokyo Women’s Medical University); Satoko Maruyama (Shinjuku Mitsui Building Clinic); Satoru Takada (Internal Medicine, Social Welfare Corporation, Shineikai Takinogawa Hospital); Shigeki Dan (Ube Internal Medicine and Pediatrics Hospital); Shigeki Nishizawa (Nishizawa Medical Clinic); Shigeo Yamashita (Department of Diabetes and Endocrinology, JR Tokyo General Hospital); Shingo Saneshige (Internal Medicine, Kamiochiai Shin Clinic); Shinichi Teno (Teno Clinic); Shinji Tsuruta (Diabetic Medicine, Itabashi Chuo Medical Center); Shinobu Kumakura (Kumakura Medical Clinic); Sumiko Kijima (Abe Hospital); Takashi Kondo (Kondo Clinic); Takeo Onishi (Internal Medicine, Onishi Clinic); Taku Kudo (Internal Medicine, Social Welfare Corporation, Shineikai Takinogawa Hospital); Tatsushi Sugiura (Internal Medicine, Seiwa Clinic); Toshihiko Ishiguro (Kaname Clinic); Yasue Suzuki (Suzuki Medical Clinic); Yasuhiro Tomita (Nakanobu Clinic); Yasuko Takano (Department of Diabetes, Shiseikai Daini Hospital); Yoshihisa Akimoto (Akimoto Yoshi Medical Clinic); Yoshiko Odanaka (Ito Internal Medicine Pediatrics Clinic); Yoshimasa Tasaka (Tokyo Women’s Medical University); Yoshitaka Aiso (Internal Medicine, Diabetes, Aiso Clinic); Yukiko Inoue (Inoue Medical Clinic); Yukinobu Kobayashi (Kobayashi Clinic).

Ethical approval and consent to participate

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. The ethics committee at the Tokyo Women’s Medical University approved the study (approval number: 2064) on 11 January 2011. Informed consent or a substitute for it was obtained from all patients before they were included in the study.

Additional information

A complete list of the JAMP (Januvia Multicenter Prospective Trial in Type 2 Diabetes) Study Investigators is provided in the “Compliance with ethical standards” section.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Supplementary material 2 (DOCX 15 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ujihara, N., Sakura, H., Hashimoto, N. et al. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study. Diabetol Int 9, 56–65 (2018). https://doi.org/10.1007/s13340-017-0330-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-017-0330-2

Keywords

Navigation